Tech Company Financing Transactions
Quentis Therapeutics Funding Round
Quentis Therapeutics, based in New York, raised $48 million from Polaris Partners, Versant Ventures and AbbVie Biotech Ventures.
Transaction Overview
Company Name
Announced On
2/28/2018
Transaction Type
Venture Equity
Amount
$48,000,000
Round
Series A
Investors
Polaris Partners (Lead Investor) (Amy Schulman)
Versant Ventures (Lead Investor) (Carlo Rizzuto)
Proceeds Purpose
The Series A proceeds will support the advancement of Quentis' lead program, a small molecule IRE1a inhibitor, into the clinic in 2019 and through clinical proof-of-concept. Additional uses of the capital include developing a pipeline of preclinical programs and building out Quentis' team.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
430 E 29th St. 1005
New York, NY 10016
USA
New York, NY 10016
USA
Phone
Website
Email Address
Overview
Immunotherapy has sparked a revolution in cancer treatment. However, despite early and significant advances with first-generation therapies, many patients do not yet benefit from immuno-oncology treatments.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Aberman
Chief Scientific Officer
Jeanne Magram
Browse more venture capital transactions:
Prev: 2/28/2018: Nomad Health venture capital transaction
Next: 2/28/2018: C2FO venture capital transaction
Share this article
Where The Data Comes From
We record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs